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Oncogene 
 An oncogene is a mutated form of a normal cellular gene – called 
a proto-oncogene – that contributes to the development of a 
cancer. 
  Proto-oncogenes typically regulate cell growth and cell 
differentiation. Most proto-oncogenes are highly conserved in 
evolutionarily diverse species, underscoring the fact that genes of 
this class play central roles in fundamental cellular processes. 
Mutations of protooncogenes that cause their conversion to 
oncogenes cause many of the perturbations in cell growth and 
differentiation that are commonly seen in cancer cells. 
 An oncogene is a type of cancer gene. While all cancer genes are 
created by mutation, oncogenes are unique in that they are 
caused by mutations that alter, but do not eliminate, the 
functions of the proteins they encode. Proteins encoded by 
oncogenes typically show an increased level of biochemical 
function as compared with the protein products of the 
corresponding, nonmutated proto-oncogene. 
 In 1908, Willhelm Ellerman and Olaf Bang demonstrated that a 
filtered extract devoid of cells and bacteria could transmit 
leukemia between chickens. 
 

 Retroviruses can cause cancer in two different ways (Depending upon 
where they integrate, proviruses can disrupt the functions of host 
genes, usually by altering their transcriptional regulation.):  
 1. slowly transforming retroviruses: a proto-oncogene can be 
changed into an oncogene upon integration of a provirus. Typically, 
cancers caused by the disruption of a host gene by a provirus have a 
long latent period and take a long time to develop. 
 2. acutely transforming retroviruses such as RSV carry their own 
cancer genes. 
 RSV contains a cancer gene known as SRC (pronounced ‘sark’). The 
protein encoded by SRC is an enzyme that localizes near the cell 
membrane and covalently modifies proteins in response to growth signals. 
Specifically, SRC encodes a protein tyrosine kinase, a class of enzymes 
that catalyzes the addition of a phosphate group onto the tyrosine 
residues of multiple protein substrates, thereby altering their function. 
Each covalent modification catalyzed by the SRC-encoded protein is one 
event of a series of enzymatically controlled events that collectively 
function to mediate signals that promote cell growth and division. In 
short, the SRC-encoded protein signals the cell to grow. 

The Search for Activated Oncogenes: 
The RAS Gene Family 

Proto-Oncogene Activation by 
Gene Amplification 
 
 
 
Proto-Oncogene Activation by 
Chromosomal Translocation 
T (8;14) 
 
 An example of a proto-oncogene that can be activated by 
chromosomal translocation is C-MYC. The expression of C-MYC is 
normally tightly regulated. This tight transcriptional control is 
altered in some lymphomas and leukemia in which the C-MYC 
gene is repositioned, via translocation, into the vicinity of a highly 
active promoter. The repositioning of C-MYC into the vicinity of 
these strong promoters is sufficient to activate C-MYC, and 
thereby convert it into a functional oncogene. 
T(9;22) 
 At the molecular level, the consequence of the 
translocation involving chromosomes 9 and 22, denoted 
t(9;22), is the unique juxtaposition of two genes, BCR and 
C-ABL. C-ABL is a proto-oncogene homologous to an 
oncogene originally found in the retroviral genome of the 
Ableson leukemia virus. In the absence of translocation, 
the expression of the C-ABL proto-oncogene is tightly 
regulated. The BCR gene, in contrast, was so named 
because of its location within the break point cluster region 
on chromosome 22. BCR expression is driven by a strong, 
constitutively active promoter. Strictly speaking, BCR is not 
considered a proto-oncogene, and in fact its normal cellular 
role is unknown. The BCR promoter functions to transcribe 
C-ABL exons when the two genes are fused by 
translocation 




PML/RARA t(15;17) Translocation 
 Acute promyelocytic leukemia (APL or AML-M3) is a subtype of acute 
myeloid leukemia with distinct clinical and histopathologic features. 
Historically one of the most lethal forms of acute myeloid leukemia, APL 
leads to disseminated intravascular coagulation and death when not 
diagnosed and treated. Treatment with all-trans-retinoic acid substantially 
improves survival in patients who have failed anthracycline chemotherapy 
or for whom anthracycline is contraindicated. Similarly, arsenic trioxide is 
beneficial in APL patients who have failed or have contraindications for 
treatment with anthracycline or retinoid-based therapy. 
 Genetically, APL is characterized by a unique chromosomal anomaly. More 
than 99% of APL patients harbor a translocation between chromosomes 
15 and 17, which fuses the retinoic acid receptor alpha (RARA) gene on 
chromosome 17 with the PML gene on chromosome 15. A short or a long 
transcript isoform is produced, depending on the PML breakpoint; the 
short isoform has been linked to poor outcome, but this association 
remains controversial. Detection of the PML/RARA t(15;17) translocation 
is diagnostic for APL, although the diagnosis can also be based on 
morphology. The presence of this translocation is necessary for response 
to all-trans-retinoic acid and arsenic trioxide. Thus, 
the PML/RARAt(15;17) assay is useful for diagnosis and predicting 
treatment response. It is also helpful for monitoring therapeutic response 
and MRD and for detecting early relapse. 
 
Clinical Use 
 
 Diagnose acute promyelocytic leukemia (APL)  
 Predict response to all-trans-retinoic acid or arsenic trioxide 
therapy 
 Assess effectiveness of therapy 
 Monitor minimal residual disease (MRD) 
 Predict early relapse 
 
Oncogenes are Dominant Cancer 
Genes 
 As we have seen throughout this chapter, a single mutation is sufficient to 
activate a proto-oncogene and convert it to an oncogene. The activating 
mutation results in a growth advantage, in spite of the continued 
presence of a normal, unmutated allele in every cell. Because the 
phenotype conferred by an oncogenic mutation is not masked by the 
presence of the remaining wild type allele, oncogenes are, by definition, 
dominant alleles. 
